Trial (ref) | Design | Latanoprost (%) | Timolol (%) | Location | Length | No | Withdrawals (%) | Sex (M/F) | Mean age (range, years) | Types of glaucoma | Baseline IOP (mean (SE)) | End point IOP (mean (SE)) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
POAG | OH | Others | Latanoprost | Timolol | Latanoprost | Timolol | |||||||||||||||||||||||
Alm et al 1995 (27) | DB-P, DB-C | 0.005 eve/mor | 0.5 bid | Scand | 6 months | 267 | 15 (6) | 116/151 | 67 (40–85) | 91 | 123 | 53 | 25.3 (0.5) | 24.6 (0.3) | 17.0 (0.4) | 17.9 (0.3) | |||||||||||||
Aquinoet al 1999 (28) | DB-P | 0.005 eve | 0.5 bid | Philippines | 3 months | 60 | / | / | / | / | / | / | 29.9 | 29 | 18.8 | 19.6 | |||||||||||||
Camras et al 1996 (29) | DB-P | 0.005 eve | 0.5 bid | USA | 6 months | 268 | 20 (7) | 114/154 | 62 (30–90) | 84 | 170 | 14 | 25.3 | 25.3 | / | / | |||||||||||||
Drance et al 1998 (30) | DB-C | 0.005 eve | 0.5 bid | Canada | 3 weeks | 36 | 3 (8) | 24/12 | 67 | 36 | 0 | 0 | 15.4 (0.4) | 15.3 (0.4) | 11.8 (0.3) | 12.2 (0.3) | |||||||||||||
Diestelhorstet al 1997 (31) | DB-P, DB-C | 0.0015/0.005 bid/eve | 0.5 bid | Germany | 6 weeks | 30 | 20 (7) | 9/21 | 62 (40–79) | 25 | 0 | 5 | 28.1 (2.6) | 27.2 (1.4) | 19.8 (2.5) | 22.6 (0.9) | |||||||||||||
Diestelhorst et al1998 (32) | DB-P | 0.005 eve | 0.5 bid | Germany | 1 month | 46 | 2 (7) | 20/26 | 60 (20–77) | 42 | 0 | 4 | 25.2 (1.2) | 24.8 (0.9) | 20.3 (0.8) | 22.7 (1.1) | |||||||||||||
Mastropasqua et al1999 (33) | DB-P | 0.005 eve | 0.5 bid | Italy | 12 months | 36 | 2 (6) | 21/15 | 46 (35–58) | 0 | 0 | 36 | 24.5 | 24.0 | / | / | |||||||||||||
Mishimaet al 1996 (34) | DB-P | 0.005 mor | 0.5 bid | Japan | 3 months | 184 | 21 (11) | 87/91 | 57 (22–81) | / | / | / | 23.1 (0.2) | 23.1 (0.2) | 16.8 (0.3) | 18.8 (0.3) | |||||||||||||
Nicolela et al 1996 (35) | DB-C | 0.005 mor | 0.5 bid | Canada | 1 week | 15 | 0 (0) | 7/8 | 63 (47–80) | 9 | 6 | 0 | 26.7 (1.3) | 26.7 (1.3) | 19.9 (0.9) | 21.4 (0.6) | |||||||||||||
Rulo et al 1994 (36) | SB-P | 0.006 bid | 0.5 bid | Holland | 1 week | 20 | 1 (5) | 8/12 | 63 (40–84) | 2 | 18 | 0 | 28.5 (1.8) | 24.2 (0.9) | / | / | |||||||||||||
Watson et al 1996 (37) | DB-P | 0.005 eve | 0.5 bid | UK | 6 months | 294 | 26 (9) | 191/103 | 65 (39–88) | 121 | 148 | 25 | 26.2 (0.3) | 26.5 (0.3) | 17.1 (0.2) | 17.7 (0.2) | |||||||||||||
Total | 1256 | 110 (9) | 597 | 593 | 410 | 465 | 137 |
No = number of patients; IOP = intraocular pressure (mm Hg); SE = standard error.
DB-P = double blind parallel, SB-P = single blind parallel, DB-C = double blind crossover, DB-P, DB-C = parallel design between latanoprost and timolol, but crossover design between different regimens of latanoprost. For example, in Alm's study,27patients receiving latanoprost were divided into two groups, one received latanoprost in the morning and placebo in the evening for 3 month and then latanoprost in the evening and placebo in the morning, another started with evening application and then switched after 3 months. In Diestelhorst's report,31 20 patients were treated with latanoprost 0.0015% twice daily or 0.005% once daily for 3 weeks in a crossover design. Ten patients received timolol 0.5% twice daily as control.
/ = not reported.
POAG = primary open angle glaucoma, OH = ocular hypertension, Others = including other types of open angle glaucoma, eg, exfoliation syndrome and pigment dispersion syndrome.
Scand = Scandinavia.
mor = morning regimen, eve = evening regimen, bid = twice per day.